Nivolumab in NSCLC

Latest evidence and clinical potential

Raghav Sundar, Byoung Chul Cho, Julie Brahmer, Ross A. Soo

Research output: Contribution to journalArticle

Abstract

New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

Original languageEnglish (US)
Pages (from-to)85-96
Number of pages12
JournalTherapeutic Advances in Medical Oncology
Volume7
Issue number2
DOIs
StatePublished - Mar 15 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Molecular Targeted Therapy
Combination Drug Therapy
Immune System
Melanoma
Neoplasms
nivolumab
Ligands
Therapeutics

Keywords

  • immune checkpoint modulator
  • nivolumab
  • non-small cell lung cancer
  • programmed death-1
  • programmed death-1 ligand

ASJC Scopus subject areas

  • Oncology

Cite this

Nivolumab in NSCLC : Latest evidence and clinical potential. / Sundar, Raghav; Cho, Byoung Chul; Brahmer, Julie; Soo, Ross A.

In: Therapeutic Advances in Medical Oncology, Vol. 7, No. 2, 15.03.2015, p. 85-96.

Research output: Contribution to journalArticle

Sundar, Raghav ; Cho, Byoung Chul ; Brahmer, Julie ; Soo, Ross A. / Nivolumab in NSCLC : Latest evidence and clinical potential. In: Therapeutic Advances in Medical Oncology. 2015 ; Vol. 7, No. 2. pp. 85-96.
@article{3bb1bd5709914e1bace4df19b7b4ea88,
title = "Nivolumab in NSCLC: Latest evidence and clinical potential",
abstract = "New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.",
keywords = "immune checkpoint modulator, nivolumab, non-small cell lung cancer, programmed death-1, programmed death-1 ligand",
author = "Raghav Sundar and Cho, {Byoung Chul} and Julie Brahmer and Soo, {Ross A.}",
year = "2015",
month = "3",
day = "15",
doi = "10.1177/1758834014567470",
language = "English (US)",
volume = "7",
pages = "85--96",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Nivolumab in NSCLC

T2 - Latest evidence and clinical potential

AU - Sundar, Raghav

AU - Cho, Byoung Chul

AU - Brahmer, Julie

AU - Soo, Ross A.

PY - 2015/3/15

Y1 - 2015/3/15

N2 - New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

AB - New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

KW - immune checkpoint modulator

KW - nivolumab

KW - non-small cell lung cancer

KW - programmed death-1

KW - programmed death-1 ligand

UR - http://www.scopus.com/inward/record.url?scp=84924809260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924809260&partnerID=8YFLogxK

U2 - 10.1177/1758834014567470

DO - 10.1177/1758834014567470

M3 - Article

VL - 7

SP - 85

EP - 96

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 2

ER -